ArticleOncoTargets and therapy2018

Clinical benefit of fulvestrant monotherapy in the multimodal treatment of hormone receptor and HER2 positive advanced breast cancer: a case series.

Orsolya Rusz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.